{"id":760,"date":"2024-10-08T02:21:55","date_gmt":"2024-10-08T02:21:55","guid":{"rendered":"http:\/\/eurosoi.org\/?p=760"},"modified":"2024-10-08T02:21:55","modified_gmt":"2024-10-08T02:21:55","slug":"kataoka-k-iwanaga-m-yasunaga-ji-et-al","status":"publish","type":"post","link":"https:\/\/eurosoi.org\/?p=760","title":{"rendered":"\ufeffKataoka K, Iwanaga M, Yasunaga JI, et al"},"content":{"rendered":"<p>\ufeffKataoka K, Iwanaga M, Yasunaga JI, et al.. 3-kinase to CTLA4-CD28 and phosphorylation of AKT and extracellular signal-regulated kinase. A CTLA4-obstructing antibody reduced cytokine-independent growth inside a dose-dependent manner. Together, these results suggest that young Japanese ATLL instances have a unique biology dependent on cell-nonautonomous relationships that drive CD28 signaling. Assessment for fusions and treatment with CTLA4 blockade should be considered in more youthful individuals with relapsed\/refractory ATLL. Visual Abstract Open in a separate window Intro Adult T-cell leukemia\/lymphoma (ATLL) is definitely a T-cell neoplasm induced by human being T-cell leukemia computer virus type 1. Recent genomic studies possess identified recurrent genomic alterations in ATLL that generally involve T-cell receptor (TCR) signaling and immune escape.1-3 Genomic alterations differ between ATLL subtypes, consistent with specific alterations promoting more aggressive phenotypes.1,4 Outcomes among individuals with aggressive subtypes remain poor, indicating a desperate need for therapies that directly target ATLL vulnerabilities.5 In Japan, the median age of ATLL demonstration in Japan is 70 years6 of age and only 5% of individuals are 50 years old.7,8 In other malignancy types, younger age is associated with <a href=\"http:\/\/www.nautilus.org\/publications\/books\/dprkbb\/uspolicy\/Elliott.html\/\">Rabbit polyclonal to PLEKHG6<\/a> unique fusions (eg, EML4-ALK in lung adenocarcinoma, ETV6-RUNX1 in B-cell leukemia).9,10 Thus, we hypothesized that ATLL in younger individuals will have distinct genetic alterations. Study design The studies were authorized by the research ethics table at Kurume University or SHP099 hydrochloride college. Nucleic acids were extracted from freezing lymph nodes. Transcriptome and DNA-targeted capture sequencing (supplemental Table 1, available on the web page) were performed and analyzed as previously reported.11 Somatic mutations were called using GeMSTONE and filtered by removing known variants. STAR-Fusion (https:\/\/github.com\/STAR-Fusion\/Star-Fusion) was utilized for gene fusion detection. Antibodies for circulation cytometry, western blot and immunohistochemistry, and additional details are included in <a href=\"https:\/\/www.adooq.com\/shp099-hydrochloride.html\">SHP099 hydrochloride<\/a> supplemental Methods. Results and conversation We performed targeted sequencing of 98 lymphoma-relevant genes11 in ATLL samples from 8 Japanese individuals 50 years old (supplemental Furniture 2 and 3). The median quantity of putative mutations was 2 (range, 0-9) (Number 1A; supplemental Table 4). All mutations except for a single mutation (case 9060) were present at variant allele frequencies consistent with heterozygosity although we cannot exclude subclonal homozygosity\/hemizygosity. The case 9060 mutation was present at high variant allele rate of recurrence consistent with homozygosity. The most frequently mutated genes were and were frequent in a earlier analysis of 370 ATLLs,2 but were not identified in our cases. The previous study2 included 9 ATLL individuals 50 years old for mutation analysis with related frequencies of genomic mutations to our cohort (supplemental Number 1a). Open in a separate window Number 1. Genomic alterations in young ATLL instances. (A) Recurrent fusions and mutations recognized in ATLL instances. The frequencies of each alteration are summarized in the middle panel comparing the current study with the previous study of 304 instances. (B) Validation of CTLA4-CD28 and ICOS-CD28 fusions by reverse transcriptionCpolymerase chain reaction. (C) Schematic representations of CTLA4-CD28 and ICOS-CD28 fusions. C, C-terminal end; Ex lover, exon; ICOS, inducible costimulator; N, N-terminal end; SP, transmission peptide; TM, transmembrane. Paired-end RNA-sequencing recognized in-frame fusions in 7 of 8 instances (87.5%) (supplemental Table 5). Among these, 3 instances (37.5%) harbored both CTLA4-CD28 and inducible costimulator (ICOS)-CD28 fusions. This contrasts with earlier reports, in which instances with both fusions were rare among peripheral T-cell lymphoma (0.3%; 1 of 273) and ATLL (1%; 1 of 105).2,12 Instances with and without CD28 fusions had related survival (supplemental Number 1b-d), as previously reported in peripheral T-cell lymphomas.12 We confirmed the presence of both fusions in all 3 instances by reverse transcriptionCpolymerase chain reaction and identified genomic breakpoints in 1 case (Number 1C; supplemental Number 1e). Isolation of ICOS-CD28 fusion breakpoints is definitely complicated from the extensive length of involved introns. CTLA4 inhibits TCR signaling while CD28 and ICOS coactivate TCR signaling through relationships with antigen-presenting cells.13 Although both CTLA4 SHP099 hydrochloride and CD28 share the ligands CD80 and CD86, the affinity to ligands is higher for CTLA4 than for CD28. The structure of the CTLA4-CD28 fusion suggests that the extracellular portion of CTLA4 is definitely expressed within the cell surface where it can interact with CD80 and CD86 to activate signaling through the intracellular CD28 portion (Number 1C). In contrast to CTLA4-CD28, the ICOS-CD28 fusion links the N-terminal signal.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\ufeffKataoka K, Iwanaga M, Yasunaga JI, et al.. 3-kinase to CTLA4-CD28 and phosphorylation of AKT and extracellular signal-regulated kinase. A CTLA4-obstructing antibody reduced cytokine-independent growth inside a dose-dependent manner. Together, these results suggest that young Japanese ATLL instances have a unique biology dependent on cell-nonautonomous relationships that drive CD28 signaling. <a href=\"https:\/\/eurosoi.org\/?p=760\" class=\"btn btn-link continue-link\">Continue Reading<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[70],"tags":[],"class_list":["post-760","post","type-post","status-publish","format-standard","hentry","category-m2-receptors"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>\ufeffKataoka K, Iwanaga M, Yasunaga JI, et al - JAK2 inhibitor against human prostate cancer cells<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/eurosoi.org\/?p=760\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"\ufeffKataoka K, Iwanaga M, Yasunaga JI, et al - JAK2 inhibitor against human prostate cancer cells\" \/>\n<meta property=\"og:description\" content=\"\ufeffKataoka K, Iwanaga M, Yasunaga JI, et al.. 3-kinase to CTLA4-CD28 and phosphorylation of AKT and extracellular signal-regulated kinase. A CTLA4-obstructing antibody reduced cytokine-independent growth inside a dose-dependent manner. Together, these results suggest that young Japanese ATLL instances have a unique biology dependent on cell-nonautonomous relationships that drive CD28 signaling. Continue Reading\" \/>\n<meta property=\"og:url\" content=\"https:\/\/eurosoi.org\/?p=760\" \/>\n<meta property=\"og:site_name\" content=\"JAK2 inhibitor against human prostate cancer cells\" \/>\n<meta property=\"article:published_time\" content=\"2024-10-08T02:21:55+00:00\" \/>\n<meta name=\"author\" content=\"info\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"info\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/eurosoi.org\\\/?p=760#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/eurosoi.org\\\/?p=760\"},\"author\":{\"name\":\"info\",\"@id\":\"https:\\\/\\\/eurosoi.org\\\/#\\\/schema\\\/person\\\/ba68ae543ef2903c0b995cd8992cedfd\"},\"headline\":\"\ufeffKataoka K, Iwanaga M, Yasunaga JI, et al\",\"datePublished\":\"2024-10-08T02:21:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/eurosoi.org\\\/?p=760\"},\"wordCount\":701,\"articleSection\":[\"M2 Receptors\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/eurosoi.org\\\/?p=760\",\"url\":\"https:\\\/\\\/eurosoi.org\\\/?p=760\",\"name\":\"\ufeffKataoka K, Iwanaga M, Yasunaga JI, et al - JAK2 inhibitor against human prostate cancer cells\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/eurosoi.org\\\/#website\"},\"datePublished\":\"2024-10-08T02:21:55+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/eurosoi.org\\\/#\\\/schema\\\/person\\\/ba68ae543ef2903c0b995cd8992cedfd\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/eurosoi.org\\\/?p=760#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/eurosoi.org\\\/?p=760\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/eurosoi.org\\\/?p=760#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/eurosoi.org\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\ufeffKataoka K, Iwanaga M, Yasunaga JI, et al\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/eurosoi.org\\\/#website\",\"url\":\"https:\\\/\\\/eurosoi.org\\\/\",\"name\":\"JAK2 inhibitor against human prostate cancer cells\",\"description\":\"Just another WordPress site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/eurosoi.org\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/eurosoi.org\\\/#\\\/schema\\\/person\\\/ba68ae543ef2903c0b995cd8992cedfd\",\"name\":\"info\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/deee51ad824afccf8f584928d162e0fea08029f81b2d40a83307df75388ac916?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/deee51ad824afccf8f584928d162e0fea08029f81b2d40a83307df75388ac916?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/deee51ad824afccf8f584928d162e0fea08029f81b2d40a83307df75388ac916?s=96&d=mm&r=g\",\"caption\":\"info\"},\"sameAs\":[\"http:\\\/\\\/eurosoi.org\"],\"url\":\"https:\\\/\\\/eurosoi.org\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\ufeffKataoka K, Iwanaga M, Yasunaga JI, et al - JAK2 inhibitor against human prostate cancer cells","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/eurosoi.org\/?p=760","og_locale":"en_US","og_type":"article","og_title":"\ufeffKataoka K, Iwanaga M, Yasunaga JI, et al - JAK2 inhibitor against human prostate cancer cells","og_description":"\ufeffKataoka K, Iwanaga M, Yasunaga JI, et al.. 3-kinase to CTLA4-CD28 and phosphorylation of AKT and extracellular signal-regulated kinase. A CTLA4-obstructing antibody reduced cytokine-independent growth inside a dose-dependent manner. Together, these results suggest that young Japanese ATLL instances have a unique biology dependent on cell-nonautonomous relationships that drive CD28 signaling. Continue Reading","og_url":"https:\/\/eurosoi.org\/?p=760","og_site_name":"JAK2 inhibitor against human prostate cancer cells","article_published_time":"2024-10-08T02:21:55+00:00","author":"info","twitter_card":"summary_large_image","twitter_misc":{"Written by":"info","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/eurosoi.org\/?p=760#article","isPartOf":{"@id":"https:\/\/eurosoi.org\/?p=760"},"author":{"name":"info","@id":"https:\/\/eurosoi.org\/#\/schema\/person\/ba68ae543ef2903c0b995cd8992cedfd"},"headline":"\ufeffKataoka K, Iwanaga M, Yasunaga JI, et al","datePublished":"2024-10-08T02:21:55+00:00","mainEntityOfPage":{"@id":"https:\/\/eurosoi.org\/?p=760"},"wordCount":701,"articleSection":["M2 Receptors"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/eurosoi.org\/?p=760","url":"https:\/\/eurosoi.org\/?p=760","name":"\ufeffKataoka K, Iwanaga M, Yasunaga JI, et al - JAK2 inhibitor against human prostate cancer cells","isPartOf":{"@id":"https:\/\/eurosoi.org\/#website"},"datePublished":"2024-10-08T02:21:55+00:00","author":{"@id":"https:\/\/eurosoi.org\/#\/schema\/person\/ba68ae543ef2903c0b995cd8992cedfd"},"breadcrumb":{"@id":"https:\/\/eurosoi.org\/?p=760#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/eurosoi.org\/?p=760"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/eurosoi.org\/?p=760#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/eurosoi.org\/"},{"@type":"ListItem","position":2,"name":"\ufeffKataoka K, Iwanaga M, Yasunaga JI, et al"}]},{"@type":"WebSite","@id":"https:\/\/eurosoi.org\/#website","url":"https:\/\/eurosoi.org\/","name":"JAK2 inhibitor against human prostate cancer cells","description":"Just another WordPress site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/eurosoi.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/eurosoi.org\/#\/schema\/person\/ba68ae543ef2903c0b995cd8992cedfd","name":"info","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/deee51ad824afccf8f584928d162e0fea08029f81b2d40a83307df75388ac916?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/deee51ad824afccf8f584928d162e0fea08029f81b2d40a83307df75388ac916?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/deee51ad824afccf8f584928d162e0fea08029f81b2d40a83307df75388ac916?s=96&d=mm&r=g","caption":"info"},"sameAs":["http:\/\/eurosoi.org"],"url":"https:\/\/eurosoi.org\/?author=1"}]}},"_links":{"self":[{"href":"https:\/\/eurosoi.org\/index.php?rest_route=\/wp\/v2\/posts\/760","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/eurosoi.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/eurosoi.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/eurosoi.org\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/eurosoi.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=760"}],"version-history":[{"count":1,"href":"https:\/\/eurosoi.org\/index.php?rest_route=\/wp\/v2\/posts\/760\/revisions"}],"predecessor-version":[{"id":761,"href":"https:\/\/eurosoi.org\/index.php?rest_route=\/wp\/v2\/posts\/760\/revisions\/761"}],"wp:attachment":[{"href":"https:\/\/eurosoi.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=760"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/eurosoi.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=760"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/eurosoi.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=760"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}